US military scientists are developing a new kind of blood test for coronavirus that could detect infection before symptoms begin, accordin...
US military scientists are developing a new kind of blood test for coronavirus that could detect infection before symptoms begin, according to a report by The Guardian.
The Defense Advanced Research Projects Agency (DARPA) is collaborating with scientists at several US universities to make a screening tool to fill the gap between nasal swabs used to detect people currently sick with COVID-19 and antibodies to detect those who have already been infected and may be immune.
It came as a result of a retooling of a program that was launched to develop a test to quickly identify when military members had been exposed to biological weapons.
Mt Sinai School of Medicine, one of DARPA's research partners, declined to specify what kind of test it's developing, but the test has the potential to diagnose coronavirus within 24 hours of infection, according to The Guardian.
The military's research arm, DARPA, is developing a new blood test for coronavirus that may be able to detect the virus much faster than current diagnostics (file)
DARPA and Mt Sinai are applying for an emergency use authorization of the test from the Food and Administration (FDA) and say they can start testing half a million people a day in the latter half of May if it's granted.
Currently, there are three types of coronavirus tests available: nasal swab diagnostics called PCR tests, antibody tests and, most recently, antigen tests.
But there are issues with each.
The swab diagnostics aren't completely reliable to detect infection until four days after after infection, and research suggests that people are contagious even earlier on and without symptoms.
Antibody tests for the blood are intended to determine who's already been infected and has begun to develop immunity to the infection.
But knowing who has the virus but is not symptomatic is both crucial to slowing its spread and very difficult to determine.
A study of a Seattle-area nursing home found that 56 percent of the people who tested positive there had no symptoms when they were tested (although half of them later developed symptoms).
It suggests that coronavirus is much more prevalent than current estimates capture, and that a test that can identify these people is much needed.
The DARPA team was developing a test that could quickly detect a soldier or citizen's exposure to germ or biological weapons, an initiative launched last year as the epigenetic characterization and observation (Echo) program.
When the pandemic broke out, the program made a quick pivot to join the COVID-19 response.
Already, it the diagnostic tool being developed there had shown its mettle for detecting other viruses.
'We have evidence that diagnosis happens in the first 24 hours for influenza and an adenovirus,' Dr Van Gieson, who was responsible for building the Echo program, told The Guardian.
'We are still in the midst of proving that with Covid-19. That said, we should know very soon after EUA.'
DailyMail.com attempted to contact both Dr Van Gieson and a Mt Sinai doctor who worked on the research for clarification on what type of test, exactly, DARPA is making, but the former did not respond to the request and the latter declined to comment.
But it has something to do with an immune response.
'Because the immune response to infection develops immediately after infection, a Covid signature is expected to provide more sensitive Covid infection diagnosis earlier,' the Mt Sina physician, Dr Stuart Sealfon told The Guardian.
Specifically, the test looks for something called target mRNA.
'Target mRNA is part of the immune response to viral infection,' Dr Sealfon said.
'mRNA expression levels really do adjust due to the presence of Covid-19. Understanding the immune response is key to fighting Covid-19.'
This expression might be detectable earlier on after infection than the antibodies serologic tests search for.
And the DARPA test might be more accurate than the various antibody tests on the market right now.
Current estimates suggest the agency's test is about 95 percent accurate.
Research detailing the test and its efficacy is expected to be released in the coming weeks, as is the FDA's decision on the EUA.
No comments